神经基因组学研究组 研究组长 乐卫东
乐卫东 教授 研究员 研究组长
wdle@sibs.ac.cn
weidongl@bcm.tmc.edu
学习经历
1973-1977 苏州医学院医学系医学学士
1980-1984 上海第二医科大学神经病学硕士
1985-1987 上海第二医科大学神经病学博士
1989-1990 美国休斯顿贝勒医学院神经病学博士后
工作简历
1983 – 1984 苏州医学院神经科主治医师、讲师
1987 – 1988 第二军医大学上海长征医院神经科主治医师、讲师
1989 – 1990 美国休斯顿贝勒医学院神经科博士后
1991 – 1992 美国休斯顿贝勒医学院神经科助理研究员
1992 – 1993 美国休斯顿贝勒医学院神经科讲师
1993 – 2000 美国休斯顿贝勒医学院神经科助理教授
2000 – 2003 美国休斯顿贝勒医学院神经科副教授，帕金森病实验室主任
2003 – 至今 中科院上海生命科学研究院研究员，
上海第二医科大学瑞金医院 神经病学教授
荣誊(证书、称号、会员)
上海第二医科大学瑞金医院生物医学研究院执行院长
上海第二医科大学神经病学研究所共同所长神经病学教授，博导
中科院百人计划入选人，中科院上海生命科学研究院研究员，博导
美国Amgen生物制药公司技术顾问
美国Pharmacia制药公司技术顾问
美国Bioirish生物信息公司高级顾问
上海枫林国际生物医学园区国外专家组成员
1984 – 至今 中华医学会神经病学学会会员
1986 – 至今 中国科学院神经科学学会会员
1991 – 至今 美国神经科学学会会员
1997 – 至今 国际运动障碍疾病学会会员
1999 – 2004 旅美科学技术协会医学与生物技术学会主任
1987 中华药学会优秀青年药学家奖。
1988 亚太药学大会优秀论文奖
1988 中 国 国家教委 二等奖
1999 第十三届国际帕金森病年会旅行基金奖。
主要成果
从事帕金森病的临床和神经药理的研究以及教学工作20余年。擅长神经生物学与分子生物学方面的工作。早在1987年就在国际生物学杂志Life Science和国家一级 杂志科学通报，中华内科、中华神经和精神病杂志上发表了6篇论文。受美国著名神经病学教授Appel的邀请，1989赴美在著名的美国德州医疗中心贝勒医学院（BaylorCollege of Medicine）神经系做博士后，现为该医学院神经病学副教授、帕金森病研究中心主任，旅美专家协会医学与生物工程学会主席。
主要研究工作包括：
(1) 帕金森病的基因特变
(2) 多巴胺神经干细胞和多巴胺株的制备
(3) Nurr1基因与多巴胺神经元发育、变性
(4) 帕金森病发病的免疫学机制
(5) 以及β淀粉样多肽损伤脑内神经元的分子生物学机制
(6) 阿尔茨海默病免疫治疗等研究，取得了重要的科研成果。
在《Proc. Natl. Acad. Sci. USA》、《Nature Genetics》、《Journal of Neuroscience》、《Cancer Research》、《Gene Therapy》、《Journal of Neurochemistry》、《JAMA》、《Annals of Neurology》、《Archive of Neurology》、《Neurology》、《Experimental Neurology》、《Journal of Neuroimmunology》、《Brain Research》、《JAMA》等国内外重要学术杂志上发表论文近90篇，其中SCI收录的62篇，被引用1300余次，并多次应邀参加国际学术会议做大会发言。应邀担任了《Life Science》 、《Analytical Biochemistry》、《Neuroscience》、《Journal of Neurochemistry》、《Cell Research》、《Journal of Neurogenetics》等杂志的审委以及《Journal of Neurology and Rehabilitation》，《Chinese Medical Journal English edition》，《Chinese Journal of Neuroscience》和《New Drugs and Remedy》的编委，NIH，VA 和新加坡科学院研究基金的评委。获得科研基金22项，包括美国NIH三项RO-1奖。
主要论文
Li XP, Yang DH, Li L, Peng CG, Chen S, Le W. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem. Int. 2007;50:959-65.
Li XP, Peng CG, Li L, M Ming, Yang DH, Le W. GDNF Protects against proteasome inhibition induced dopaminergic neuron degeneration by inhibition of endoplasmic reticulum stress and caspase-3 activation. Journal of Gerontology: Biological Sciences, 2007 (in press).
Li R, Peng N, Li XP, Le WD**. (2006) (-)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway. Brain Res. 1097:85-89
Deng H, Le WD*, Xie W, Jankovic J. (2006) Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 112:454-457.
Deng H, Xie W, Guo Y, Le WD, Jankovic J. (2006) Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord 21(5):728-9.
Deng H, Le WD*, Hunter CB, Ondo WG, Guo Y, Xie WJ, Jankovic J. (2006) Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 63(2):273-7.
Chu Y, Le WD*, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. (2006) Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494(3):495-514.
Pan T, Li X, Xie W, Jankovic J, Le WD**. (2005) Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 579(30):6716-20.
Deng H, Jankovic J, Guo Y, Xie W, Le WD**. (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 337(4):1133-8.
Deng H, Le WD*, Guo Y, Huang MS, Xie WJ, Jankovic J. (2005) Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 65(4):651-2.
Zhang X, Xie W, Qu S, Pan T, Wang X, Le WD**. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333(2):544-9.
Du F, Li R, Huang Y, Li X, Le WD**. (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Euro J of Neuosci 22(10): 2422-2430.
Deng H, Le WD*, Jankovic J. (2005) Genetic analysis of LRRK2 gene mutations in Parkinson disease. Annals of Neurology 57:933-934
Imam S, Jankovic J, Ali S, Skinner JT, Xie W, Conneely OM, Le WD**. (2005) Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. FASEB 19(11):1441-50.
Deng H, Xie WJ, Le WD*, Huang MS, Jankovic J. (2006) Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett 401(1-2):16-9.
Liu X, Fan XL, Lu GR, Li R, Li XP, Le WD**. (2005) Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both ERα and ERβ in microglia. Journal of Neuroscience Research 2005;81(5):653-65.
Li Z, Szurek PF, Jiang C, Pao A, Bundy B, Le WD, Bradley A, Yu YE. (2005) Neuronal differentiation of NTE-deficient embryonic stem cells. Biochem Biophys Res Commun 330(4):1103-9
Qu S, Ondo WG, Zhang X, Xie WJ, Pan TH, Le WD**. (2005) Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp Brain Res 168(1-2):152-6.
Cai W, Khaoustov VI, Xie Q, Pan T, Le WD, Yoffe B. (2005) Interferon-(-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. Journal of Hepatology 42:880-887
Deng H, Le WD*, Xie WJ, Pan TH, Zhang X, Jankovic J. (2005) Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset Parkinsonism. Neuroscience Letters 382:297-299
Pan TH, Jankovic J, Le WD**. (2005) Biological effects of pramipexole on dopaminergic neuron associated genes: a relevance to neuroprotection. Neuroscience Letter 377:106-109
Deng H, Le WD*, Jankovic J. (2005) G309D and W4370PA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurologica Scandinavica 111:351-352
Jiang CT, Wan XH, He Y, Pan TH, Jankovic J, Le WD** (2005) Age-dependent dopaminergic dysfunction in Nurr1 knock-out mice. Experimental Neurology 191:154-162.
Yang, JH, Le WD, Basinger SF, Wu SM, Yang CY. (2005) Mechanisms of apoptosis in human retinal pigment epithelium induced by TNF-( under conditions of heavy metal ion deficiency. Investigative Ophthalmology & Visual Science 46:1039-1046
Deng H, Le WD*, Jankovic J (2004). Parkinson's Disease, Essential Tremor, and Premutation Alleles of the FMR1 Gene. JAMA 292:1685-1686
He Y, Imam SZ, Dong Z, Jankovic J, Ali S, Appel SH, Le WD**. (2003) Role of nitric oxide in rotenone-induced nigro-striatal injury. Journal of Neurochemistry 86:1338-1345
Le WD and Appel SH. (2004) Mutant genes responsible for Parkinson's disease. Current Opinion in Pharmacology 4:79-84
Thomas M and Le WD** (2004) Minocycline: Neuroprotective mechanisms in Parkinson's disease. Current Pharmaceutical design 10:679-686
Pan T, Le WD*, Jankovic J (2004) Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 62:343-344
Jiang CT, Wan XH, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, Sundsmo JS, Le WD** (2004) Dopaminergic properties and experimental anti-parkinsonian effects of IPX-750 in rodent models of Parkinson disease. Clinical Neuropharmacology 27:63-73
Xu PY, Le WD**, (2004) Novel splicing variant of the human orphan nuclear receptor Nurr1 gene. Chinese Medical Jounal (Engl) 117:899-902
Rachakonda V Pan T, Le WD**, (2004) Advances in the Research of Biomarkers of Neurodegenerative Diseases. Cell Research 14:347-358
Li R, Huang YG, Du F, Le WD**, (2004) (-)-Epigallocatechin Gallage Inhibits Lipopolysaccharide-Induced Microglial Activation and Protects against Inflammation-Mediated Dopaminergic Neuronal Injury. Journal of Neuroscience Research 78:723-731
Zhou WH, Xie WJ, Le WD, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH (2004). Activated microglia initiate motor neuron injury by a glutamate-mediated mechanism. Journal of Neuropathology and Experimental Neurology 63:964-977
Le WD, Xu P.Y, Jiang H, Jankovic J, Appel S.H, Vassilatis D. (2003) Mutations in NNR4A2 associated with familial Parkinson's disease. Nature Genetics 33:85-89
Pan T, Jankovic J, Le WD**. Green tea polyphenols and Parkinson disease. (2003) Aging & Drugs 20:1-12.
Pan T, Fei J, Zhou X.D, Jankovic J, Le, WD**. (2002) Effects of green tea polyohenols on dopamine uptake and on MPP+-induced dopamine neuron injury. Life Sciences 72:412-418
Shine H.D, Zhou L, Grider M.H, McGowen L.R, Menesses-Diaz D.A, Zheng X, Le WD, Manounas L. (2002) Neurotrophic factor gene delivery supports axonal regeneration after injury. Journal of Neurochemistry 81:85-86
He Y, Le WD*, Xie W.J, Appel S.H. (2002) Role of FcR in the nigral injury induced by IgG from Parkinson's disease. Experimental Neurology 176:322-327
Mohamed H.S, Mosier D.R, Zou L.L, Sikolos L, Alexianu M.E, Engelhardt J.I, Beers D.R, Le WD, Appel S.H. (2002) Immunoglobulin FcR receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. Journal of Neuroscience Research 69:110-116
Xu P.Y, Liang R, Tan E.K, Ashizawa T, Jankovic J, Le WD**. (2002) Association of homozygous 7048G7049 variant in intron 6 of Nurr1 gene with Parkinson's disease. Neurology 58:881-884
Le WD, Rowe D, Xie W.J, He Y, Appel S.H. (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. Journal of Neuroscience 21:8447-8455.
Xu P.Y, Jankovic J, Le WD**. (2001) Identification of a high frequency of mutation at exon 8 of ATP7B gene in Chinese population with Wilson's disease by fluorescent PCR. Archive of Neurology 58:1879-1882
He Y, Appel S.H, Le WD.** (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Research 909:187-193
Xu F, Xia W, Zhao S, Peng H, Luo, R.Z, Dai J, Long Y, Zou L.L, Le WD, Parlow A.F, Hung M.C, Bast R.C, Yu Y. (2000) ARHI acts as a growth inhibitor in transgenic mice. Cancer Research 60:4913-4920
Engelhardt J.I, Le WD*, Xie W.J, Siklos L, Appel S.H. (2000) Experimental cholinergic neuron degeneration of basal forbrain by stereotaxic injection of Alzheimer disease immunoglobulins. Archive of Neurology 57:681-686
Le WD, Xie W.J, Jankovic J, Appel S.H. (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. Journal of Neurotransmission 107:1165-1173
Zou L.L, Xu J, He Y, Jankovic J, Appel S.H, Le WD**. (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin MPTP in C57BL/6 mice. Neuroscience Letters 281:167-170
Ondo WG, He Y, Rajasekaran S, Le WD**. (2000) Clinical correlates of 6-hydroxydopamine injection into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Movement Disorders 15:154-158
Le WD. Conneely O.M, He Y, Saucedo-Cardenas O, Jankovic J, Appel S.H. (1999) Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. Journal of Neurochemistry 73:2218-222
Le WD. Conneely O.M, Zou L.L, He Y, Jankovic J, Appel S.H. (1999) Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Experimental Neurology 159:451-458
Zou L.L, Huang L, Hayes RL, Black C, Qiu YH, Perez-Polo J.R, Le WD, Clifton G.L, and Yang K. (1999) Liposome-mediated NGF transfection following neuronal injury: potential therapeutic applications. Gene Therapy 6:994-1005
Le WD, Xie W.J, and Appel SH.(1999) Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. Journal Neuroscience Research 56:652-658
Zou L.L, Jankovic J, Rowe D.B, Xie W.J, Appel S.H, and Le WD**. (1999) Neuroprotection by pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sciences 64:1275-1285
Le WD., Rowe D.B, Jankovic J, Xie W.J, and Appel S.H. (1999) Effects of cerebrospinal fluid from patients with Parkinson's disease on dopaminergic cells. Archive Neurology 56:194-200
Rowe D.B, Le WD, Smith R.G, and Appel S.H. (1998) Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. Journal Neuroscience Research 53:551-558
Saucedo-Cardenas O, Quintana-Hau J.D, Le WD, et al. (1998) Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA. 95:4013-4018
Chen S., Le WD*, Xie W.J, Alexianu M.W, Engelhardt J.I, Siklos L, Appel S.H. (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Archive Neurology 55:1075-1080
Kalman J, Engelhardt JI, Le WD, Xie W, Szabo I, Kasa P, Appel SH (1997) Experimental immune-mediated damage of septal cholinergic neurons. Journal of Neuroimmunology 77:63-74
Le WD, Xie WJ, Kong R, Appel SH (1997) (-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of (-amyloid precursor protein. Journal of Neurochemistry 69:978-985
Le WD, Jankovic J, Xie WJ, Kong R, Appel S (1997) (-)Deprenyl protection of 1-methy-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neuroscience Letters 224:197-200
Le WD, Yang K, Whitson JS, Clifton GL, Hayes RL (1996) Liposome-mediated GNF gene transfection increases ChAT activity in CNS cell cultures. Neuroreport 7(3):1-3
Le WD, Nyormoi O, Xie W, Smith RG, and Appel SH. (1995) (-amyloid 1-40 increase expression of (-amyloid protein precursor in neuronal hybrid cells. Journal of Neurochemistry 65:2373-2376
Le WD, Colom LV, Xie WJ, Smith RG, Appel SH (1995) Cell death induced by (amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA gated channel activation leading to apoptosis. Brain Research 686:49-60
Le WD, Engelhardt JI, Xie W, Appel SH (1995) Experimental autoimmune nigra damage in guinea pigs. Journal of Neuroimmunology 57:45-53
Le WD, Engehardt JI, Xie W, Appel SH (1993) Immune invasion with serum against DA neurons induces a parkinsonian model in rats. Movement Disorders 8:409
Le WD, Xie W, Smith RG, Appel SH (1993) Protective effects of IGF-1, bFGF, EGF, NGF and cAMP on oxidation and hypoglycemia induced damage in hybrid dopaminergic cells. Neurodegeneration 2:227-236
Appel SH, Le WD*, Tajti J, Haverkamp LJ, Engelhardt JI (1992) Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs. Annals of Neurology 32: 494-501
Le WD, Bostwick JR, Appel SH (1992) Use of 3H-GBR12935 to measure dopaminergic nerve terminal growth into rat striatum. Developmental Brain Research 67:375-377
Crawford GD, Le WD, Smith RG, Xie W, Stefani E, Appel SH (1992) A novel N18TG2 X mesencephalon cell hybrid expresses properties which suggest a dopaminergic cell line of substantia nigra Origin. Journal of Neuroscience 12(9):3392-3398
Rabinovsky ED, Le WD, McManaman JL (1992) differential effects of neurotrophic factors on neurotransmitter development in the IMR-32 human neuroblastoma cell line. Journal of Neuroscience 12 (1): 171-179
Bostwick JR, Le WD**, (1991) A tyrosine hydroxylase assay in microwells using coupled nonenzymatic decarboxylation of DOPA. Analytical Biochemistry 192: 125-130
Le WD, Jiang G, Zhou X, (1988) Enhanced stereotypic behavior by chronic treatment with bromocriptine accompanied increase of D-1 receptor binding. Life Sciences 42:1841-1845
专著与综述
邀请撰写和发表的综述
(1). Le WD and Appel SH. (2004) Mutant genes responsible for Parkinson’s disease.
Current Opinion in Pharmacology 4:79-84
(2). Thomas M and Le WD (2004) Minocycline: Neuroprotective mechanisms in
Parkinson’s disease. Current Pharmaceutical design: 10:679-686
(3) Rachakonda V， Pan TH， Le WD. (2004) Biomarkers of neurodegenerative disorders:
how good are they? Cell Research 14:347-358
(4). Du F， Li R， and Le W.D. (2003) Gene expression and regulation in
dopamine neuron development. Chinese Journal of Neurosciences. 5:8-15
(5). Li R and Le W.D. (2003) Green tea polyphenols: Neuroprotective
mechanisms in Parkinson Disease. Clinical Neurosciences. 10:201-214
(6). Du F and Le W.D. (2003) Dopamine agonists and neuroprotection in
Parkinson disease. Chinese Journal of Nervous Disoders. 28:180-192
(7). Thomas M， Le W.D， and Jankovic J. (2002) Minocycline:
A neuroprotective strategy in neurodegenerative disorders. Archives of Neurology. 26:18-23
(8). Xu P.Y. and Le W.D. (2002) Nurr1 gene and dopamine neuron function
in neuro-psychological disorders. International Review of Neurology and
Neuropsychiatry. 27:12-22
(9). Xu P.Y. and Le W.D. (2001) Research update in restless leg syndrome.
Chinese Journal of Clinical Neurosciences. 9:398-401
(10). Dong Z.J. and Le W.D. (2001) Rotenone neurotoxicity and Parkinson’s disease.
International Review of Neurology and Neuropsychiatry. 28:357-360
(11). Le W.D. (2001) Mechanisms of Action of Pramipexole:
Putative Neuroprotective Effects. Reviews in Contemporary Phamacotherapy. 12:33-52.
(12). Le W.D. and Jankovic J (2001) Do dopamine agonists have neuroprotection?
Drugs and Aging. 18:389-396.
(13). Le W.D (1986) MPTP and Parkinson disease (review in Chinese).
World Science， 3:76-79
参加国际会议的论文
(1). Qu S， Zhang X， Xie W， Pan T， Ondo W， Le WD (2004) Projections of diencephalic
dopaminergic cells into the spinal cord of mice. Society for Neuroscience Meeting
Program， 945.1
(2) Chu Y， Kompoliti K， Le WD， Farrer MJ， Trojanowski JQ， Mufson EJ， Kordower JH.
(2004) Nurr1 expression in nigral dopaminergic neurons in Parkinson’s disease
and related disorders. Society for Neuroscience Meeting Program， 879.11
(3) Grider MH， Le WD， Shine HD. (2004). In situ expression of BDNF or NT-3 promotes
sprouting of lesioned serotonergic axons. Society for Neuroscience Meeting Program， 834.10
(4). Le W.D， Jiang Q， Xie W.J， Hintermann S， Jankovic J (2004) Nurr1 gene targeting
therapy for Parkinson’s disease. Movement Disorders 19 (Supple 9): S132
(5) Jiang C， Pan T， Jankovic J， Le WD (2004) Effects of ropinirole on progression
of Parkinsonism in Nurr1-deficient mice and its underlying mechanisms.
Neurology 62 (Suuple 5):A7
(6) Jiang C， Wan X， Jankovic J， Le WD (2004) Dopaminergic properties and anti-parkinsonian
effects of IPX-750 in rodent models of Parkinson’s disease. Neurology 62
(Suppl 5): A9
(7). Pan T， Jankovic J， Le WD (2004) The pharmacological and biological effects of
pramipexole on dopamine transporter. Neurology 62 (Suppl 5):A109
(8). Pan T， Xie WJ， Jankovic J， Le WD (2004) Decreased Nurr1 mRNA in peripheral blood
lymphocytes in Parkinson’s disease. Neurology 62 (Suppl 5): A108
(9). Le W.D， Imam S， He Y， Dong Z.Q， Jankovic J， Appel S.H. (2003) Nitric oxide
mediated neurotoxicity in rotenone treated mice. IBRO meeting. Neurosciences 58 (Suppl):28
(10). Xu P.Y， Jankovic J， Le W.D. (2001) Using fluorescent PCR to screen Arg778Leu mutation
at exon 8 of ATP7B gene in Chinese population with Wilson disease. Neurology Suppl (3):A417
(11). Le W.D， Xu P.Y， Liang R， Tan EK， Jankovic J. (2001) Polymorphism at intrn 6 of
Nurr1 gene is associated with familial Parkinson disease. Neurology Suppl (3):A129
(12). Le W.D， He Y， Jankovic J. (2001) Aged Nurr1+/- mice develop
behavioral and biochemical changes consistent with Parkinsonism. Abstract of XIV
International Congress on Parkinson’s disease. Helsinki， Finland.
(13). Le W.D. Dong Z.J， He Y， Jankovic J. (2001) Chronic administration of rotenone
induces moderate dopaminergic dysfunction in mice. Abstract of XIV International Congress
on Parkinson’s disease. Helsinki， Finland.
(14). Le WD， Xie W， Jankovic J， Kong R， Appel S. (1996) Dopaminergic neurotoxicity of
cerebrospinal fluid from patients with Parkinson’s disease.
Movement Disorder 11(5):2
(15). Le W.D， Conneely O.M， Jankovic J， Appel S.H. (2000) Reduction of Nurr1 gene
expression is a potential risk factor for the nigral Daergic degeneration in PD. Movement
Disorders Suppl 3:192
(16). Rowe D.B， Le W.D， Jankovic J， Hunter C， Appel S.H. (2000) Antibodies from
patients with Parkinson’s disease with protein modified by dopamine
oxidation. Movement Disorders Suppl 3:28
(17). Le W.D， Conneely O.M， Jankovic J， Appel S.H. (2000) Nurr1 gene expression and
dopamine neuron degeneration relevant to Parkinson’s disease.
Neurology Suppl 3: A53
(18). Le W.D， Zou L.L， Xu J， Jankovic J. (1999) Antioxidant property of pramipexole in
neuroprotection. Parkinsonism & Related Disorders. 5 (Supple):S78
(19). Le W.D， Rowe D.B， Xie W.J， Appel S.H. (1999) Activated microglia induced dopaminergic
cell injury in vitro. Parkinsonism & Related Disorders. 5 (Supple):S19
(20). Le W.D， Asaka T， Xie W.J， Appel S.h. (1998) The role of oxidative stress in the
production of b-APP and b-amyloid. Neurobiology of Aging 19
(Supple):S265
论著
(1). Appel SH， Smith RG， Le W.D (1996) Immune-mediated cell death
in neurodegenerative disease. Advance in Neurology， 69:153-158
(2). Appel SH， Smith RG， Le W.D (1996) Neurodegeneration and neuroprotection
in Parkinson’s disease. Olanow CW， Jenner P， Youdim M (eds)， Academic Press， pp 187-203
(3). Le W.D (2004) Neurotransmitters and receptors in Parkinson’s disease.
Edited by Chen SD et al In: Parkinson’s disease. Medical Science Press， Beijing.
QQ:
: